Search for Clinical Trial Results
Hemoglobinuria - 76 Studies Found
Status | Study |
Recruiting |
Study Name: Proof of Concept Study to Assess the Efficacy, Safety and Pharmacokinetics of LFG316 in Patients With Paroxysmal Nocturnal Hemoglobinuria Condition: Paroxysmal Nocturnal Hemoglobinuria PNH Date: 2015-08-07 Interventions: Biological: LFG316 LFG316 will be administered to all patients enrolled in the study |
Terminated |
Study Name: Safety and Pharmacokinetics of TT30 in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2011-04-12 Interventions:
|
Not yet recruiting |
Study Name: ALXN1210 Versus Eculizumab in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2017-02-14 Interventions:
|
Recruiting |
Study Name: ALXN1210 Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Nocturnal Hemoglobinuria (PNH) Date: 2016-10-25 Interventions:
|
Completed |
Study Name: Eculizumab Pharmacokinetics/Pharmacodynamics Study in Pediatric/Adolescent PNH Subjects Condition: Hemoglobinuria, Paroxysmal Date: 2009-03-23 Interventions: Drug: Eculizumab Other Name: Soliris |
Completed |
Study Name: Paroxysmal Nocturnal Hemoglobinuria Human Anti-Human Antibodies Study Condition:
Date: 2011-08-05 |
Completed |
Study Name: Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Condition: Paroxysmal Hemoglobinuria, Nocturnal Date: 2005-07-20 Interventions:
|
Active, not recruiting |
Study Name: A Open-label, Multiple Ascending Dose Study to Evaluate the Efficacy, Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of ALXN1210 Administered Intravenously to Patients With Paroxysmal Nocturnal Hemoglobinuria Condition:
Date: 2015-11-11 Interventions:
|
Approved for marketing |
Study Name: The Paroxysmal Nocturnal Hemoglobinuria Early Access Treatment Protocol Condition: Hemoglobinuria, Paroxysmal Date: 2007-02-20 Interventions: Drug: eculizumab 600mg IV every week and 900mg IV every 2 weeks |
Completed |
Study Name: Study Using Eculizumab in Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients Condition: Hemoglobinuria, Paroxysmal Date: 2005-07-18 Interventions: Drug: eculizumab |